Baruch Brenner
Clinical trials sponsored by Baruch Brenner, explained in plain language.
-
Promising combo targets tough esophageal cancer
Disease control OngoingThis study tested whether adding two immunotherapy drugs, nivolumab and cetuximab, to standard chemoradiation could improve outcomes for people with a certain type of advanced esophageal cancer. Twelve participants who had not received prior treatment received the drug combinatio…
Phase: PHASE2 • Sponsor: Baruch Brenner • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Immunotherapy boosts rectal cancer treatment in early trial
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy and radiation can improve outcomes for people with locally advanced rectal cancer. About 29 participants who have not had prior treatment will receive the combination before surgery. The mai…
Phase: PHASE2 • Sponsor: Baruch Brenner • Aim: Disease control
Last updated May 11, 2026 20:38 UTC